infections

Clinically tested probiotics for common colds management designed by SynBalance

A new scientific publication on the beneficial effect of probiotics on cold symptoms relief, immune response enhancement, and quality of life in healthy adults during winter seasons.

How C. difficile uses unique enzyme to survive in the gut

Targeting TudS could be a potential therapeutic approach for treating C. difficile infections.

Gut bacteria linked to worsening infections in lung disease

Targeting E. lenta or boosting neutrophil function may lead to new treatment strategies for bronchiectasis and related lung diseases.

Synthetic microbial communities may help to fight C. difficile infection

Nutrient competition is the main mechanism of C. difficile inhibition, hinting at the potential for targeted therapies with probiotics instead of traditional FMT.

The need for diversity in vaginal microbiota research

By addressing biases and increasing diversity in microbiota studies, researchers can develop more accurate and inclusive health strategies for women of different backgrounds.

Ferring receives health Canada approval for REBYOTA

The approval is major step forward in the fight against recurrent C. diff infection.

Vaginal microbiota may be linked to increased Chlamydia infection risk

Certain features of the vaginal microbiota, including specific bacterial communities, could indicate an increased Chlamydia infection risk.

The vaginal microbiome

Understanding the vaginal microbiome is essential not only for treating gynecological conditions but also for preventing them and promoting overall well-being.

SER-155’s early success in stem cell transplants: reducing infections and improving outcomes

Chris Ford, Senior Vice President, Translational Biology at Seres Therapeutics, discusses the development of SER-155, a cultivated bacterial consortium designed to address the unmet medical need of preventing bloodstream infections…

The evolution of REBYOTA: milestones in microbiome-based therapeutics

On the second anniversary of its launch, Ferring Pharmaceuticals’ REBYOTA remains a landmark innovation in the prevention of recurrent Clostridioides difficile.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top